PAEDIATRIC HYPERTENSION

PAEDIATRIC HYPERTENSION: A CLINICAL REVIEW OF EMERGING RISK FACTORS AND MODERN MANAGEMENT STRATEGIES An article by RIDDHI NAGPURE under the guidance of MUKTARALI KYZY BEGIMAI Ma’am (Faculty of paediatrics and childhood diseases). ABSTRACT Hypertension in children and adolescents has become a primary diagnosis, presenting significant challenges for healthcare providers. The prevalence rates have increased significantly, with rates rising to 9.43% among children with obesity and 14.7% in those with severe obesity. The pathophysiology of paediatric hypertension is complex, involving sympathetic nervous system activation, renin-angiotensin-aldosterone system dysregulation, renal compression mechanisms, and insulin resistance pathways. Screening recommendations emphasize annual blood pressure measurements starting at age 3 and ambulatory blood pressure monitoring. Treatment strategies include lifestyle modifications, pharmacological interventions, precision medicine applications, novel therapeutics, and technology-assisted monitoring. The long-term implications of paediatric hypertension include target organ damage and increased risk of adult cardiovascular disease. Keywords: paediatric hypertension, childhood blood pressure, obesity, hypertension screening, ambulatory blood pressure monitoring, lifestyle modifications, pharmacological treatment, cardiovascular risk 1. INTRODUCTION Hypertension, once considered primarily an adult condition, is increasingly recognized as a significant health concern in the paediatric population. Over recent decades, there has been a notable shift in the epidemiology of childhood hypertension, with primary hypertension becoming more prevalent alongside traditional secondary causes. This comprehensive review examines the current understanding of paediatric hypertension, with a particular focus on emerging risk factors, screening protocols, and evolving management strategies. 2. PREVALENCE AND EPIDEMIOLOGICAL TRENDS The prevalence of paediatric hypertension has shown concerning trends in recent years. According to recent studies, hypertension affects approximately 3-5% of children and adolescents between ages 1 to 18 years. However, when applying the 2017 American Academy of Paediatrics (AAP) guidelines, the prevalence increases, with data from the National Health and Nutrition Examination Survey (NHANES) showing rates of 4.2% among all children aged 12-19 years between 2013 and 2016. More alarmingly, the prevalence is significantly higher in children with obesity, reaching 9.43% in obese children and 14.7% in severely obese children during the same period. This marked increase highlights the strong association between excess weight and hypertension in paediatric populations. A global meta-analysis of 47 articles revealed a pooled prevalence of hypertension at 4.0% (95% CI, 3.29-4.78%) and prehypertension at 9.67% (95% CI, 7.26-12.38%). Furthermore, data from the International Childhood Cardiovascular Cohort Consortium (i3C) showed that after applying the 2017 guidelines, the prevalence of stage I hypertension increased from 7.6% to 13.5%, and stage II hypertension from 1.3% to 2.5% among children with a mean age of 10.4 years. 3. EMERGING RISK FACTORS 3.1 Obesity and Metabolic Factors: Obesity remains the most significant modifiable risk factor for paediatric hypertension. The relationship between excess weight and blood pressure is well-established, with studies showing that children with persistently high BMI have 1.53 times higher risk of hypertension for boys and 1.28 times higher for girls compared to those with consistently low BMI. The prevalence of hypertension increases dramatically with weight status, from 2% in children with BMI below the 5th percentile to 11% for those above the 95th percentile. Insulin resistance has emerged as a potential mechanism linking obesity to hypertension. Research using glucose clamp techniques has demonstrated that baseline fasting insulin at age 13 predicts follow-up blood pressure and clustered cardiovascular risk factors at age 19. This supports the hypothesis that metabolic dysfunction plays a crucial role in the development of hypertension in youth. 3.2. Demographic and Socioeconomic Factors: Sex and racial disparities in paediatric hypertension have been consistently observed. The Bogalusa Heart Study has demonstrated higher blood pressure levels in males and in Black children of both sexes starting around 12 years of age. Blood pressure increases at a greater rate in males than females from adolescence to young adulthood, suggesting hormonal influences on blood pressure regulation during puberty. Socioeconomic factors have emerged as important considerations in understanding paediatric hypertension risk. Low childhood socioeconomic status has been linked to adult hypertension, suggesting early life programming of cardiovascular risk. This may reflect differences in access to care, adherence to treatment, nutritional quality, physical activity opportunities, and stress associated with structural racism and social disadvantage. 3.3. Dietary Factors: High sodium intake appears to have a synergistic effect with obesity on blood pressure elevation in children and adolescents. Additionally, consumption of sweetened beverages, processed foods high in sodium, and diets low in fruits and vegetables have been associated with increased hypertension risk in paediatric populations. 3.4. Environmental Factors: Emerging research has begun to explore the impact of environmental exposures, including air pollution, on paediatric hypertension risk. While this area requires further investigation, initial findings suggest that environmental factors may contribute to hypertension development in susceptible individuals. 4. PATHOPHYSIOLOGY OF PAEDIATRIC HYPERTENSION Multiple mechanisms contribute to the development of hypertension in children, particularly in the context of obesity. These include: Sympathetic Nervous System (SNS) Activation: Increased sympathetic activity is a key mechanism in obesity-related hypertension, leading to increased heart rate and peripheral vascular resistance. Renin-Angiotensin-Aldosterone System (RAAS) Activation: Obesity disrupts normal RAAS suppression, contributing to sodium retention and blood pressure elevation. Renal Compression: Fat accumulation around the kidneys results in increased renal sodium reabsorption and impaired pressure natriuresis, essential factors in blood pressure regulation. Insulin Resistance: Altered insulin signaling affects vascular function and contributes to sodium retention, playing a role in hypertension development. 5. SCREENING AND DIAGNOSIS GUIDELINES 5.1 Current Recommendations: The American Academy of Paediatrics guidelines recommend annual blood pressure screenings starting at age 3 and monitoring at every healthcare visit for children with risk factors such as obesity. Initial measurements can use oscillometric devices, but elevated readings require confirmation with auscultatory methods. The diagnostic criteria for paediatric hypertension differ from adult standards. In children, hypertension is defined as blood pressure ≥95th percentile on three separate occasions, adjusted for age, sex, and height. The 2017 guidelines also introduced absolute thresholds for adolescents, defining hypertension as ≥130/80 mmHg for those 13 years and older, aligning with adult criteria. 5.2 Ambulatory Blood Pressure Monitoring: Ambulatory Blood Pressure Monitoring (ABPM) has emerged as a valuable tool in paediatric hypertension assessment. The 2017 guidelines recommend ABPM for confirmation of hypertension in youth with elevated BP for 1 year or stage 1 hypertension over 3 visits. This helps identify white coat hypertension, which is particularly prevalent in obese youth, and masked hypertension, which occurs when office readings are normal but ambulatory measurements show elevation. ABPM has demonstrated superior predictive value for target organ damage, particularly left ventricular hypertrophy, compared to office measurements. However, challenges remain with ABPM accessibility, standardization, and patient adherence. 6. Management Strategies 6.1. Lifestyle Modifications: Lifestyle modification forms the foundation of paediatric hypertension management. Key components include: Dietary Approaches: The Dietary Approaches to Stop Hypertension (DASH) diet has been adapted for adolescents with promising results. It focuses on sodium restriction (<2300 mg/day), reducing high-fat dairy and added sugars, and increasing intake of fruits, vegetables, legumes, and whole grains. Clinic-based behavioral nutrition intervention programs using the DASH diet have shown greater efficacy in reducing systolic blood pressure compared to routine care nutritional counseling. Physical Activity: Regular physical activity is recommended to improve cardiovascular fitness and assist with weight management. Current guidelines recommend 60 minutes of moderate to vigorous physical activity daily for children and adolescents. Weight Management: Given the strong association between obesity and hypertension, weight management is crucial. Studies indicate that a 1.6 kg/m² decrease in BMI can achieve approximately a 10 mm Hg reduction in systolic blood pressure. Intensive health behavior and lifestyle treatments featuring at least 26 hours of face-to-face, family-based contact time with multicomponent interventions have shown the best results. 6.2. Pharmacological Treatment: When lifestyle modifications are insufficient, pharmacological intervention becomes necessary. The 2017 AAP guidelines recommend initiating pharmacotherapy for: Children with symptomatic hypertension Secondary hypertension Hypertensive target-organ damage Diabetes (types 1 and 2) Persistent hypertension despite lifestyle modification First-line medications typically include: Angiotensin-Conver